OverviewSuggest Edit

Vivos is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. The Company is engaged in the development of RadioGel, an Yttrium-90 based brachytherapy device, for the treatment of tumors.

TypePublic
Founded2006
HQRichland, US
Websiteradiogel.com

Latest Updates

Employees (est.) (Feb 2019)2(-50%)
Revenue (FY, 2019)$9.5 K(+135%)
Share Price (Oct 2020)$0 (+2%)
Cybersecurity ratingAMore

Key People/Management at Vivos

Carlton Cadwell

Carlton Cadwell

Director, Chairman of the Board
Michael Pollack

Michael Pollack

Interim CFO
Mike Korenko

Mike Korenko

Director, President CEO
David J. Swanberg

David J. Swanberg

Chief Technical Manager
Show more

Vivos Office Locations

Vivos has an office in Richland
Richland, US (HQ)
719 Jadwin Ave
Show all (1)

Vivos Financials and Metrics

Vivos Revenue

Vivos's revenue was reported to be $9.50 k in FY, 2019
USD

Net income (Q1, 2020)

(360.2k)

EBIT (Q1, 2020)

(120.4k)

Market capitalization (19-Oct-2020)

6.1m

Closing stock price (19-Oct-2020)

0.0

Cash (30-Jun-2020)

248.9k

EV

6.0m
Vivos's current market capitalization is $6.1 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

393.6k248.0k140.6k24.1k24.1k8.1k4.1k9.5k

Cost of goods sold

64.0k72.8k105.3k1.1k474.02.5k2.5k2.5k6.0k

Gross profit

329.6k175.1k35.3k23.0k23.6k5.6k1.6k3.5k

Gross profit Margin, %

84%71%25%95%98%69%38%37%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

139.9k55.6k48.6k67.4k65.3k24.8k24.8k115.8k14.1k10.1k12.1k12.1k4.1k4.1k4.1k8.0k

Cost of goods sold

11.5k17.1k16.9k18.3k22.3k4.6k4.6k100.3k251.0301.0265.0390.085.02.5k

Gross profit

128.5k38.4k31.7k49.1k43.0k20.2k20.2k15.5k13.8k9.8k11.7k

Gross profit Margin, %

92%69%65%73%66%82%82%13%98%97%97%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

52.6k6.4k203.0179.0k27.9k8.3k5.5k20.4k

Accounts Receivable

13.7k21.2k

Prepaid Expenses

1.1k2.3k3.3k21.7k26.2k12.0k6.7k11.0k23.5k

Inventories

9.7k4.1k8.5k8.5k8.5k8.5k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

5.1k18.7k13.3k13.8k47.4k67.5k7.0k26.2k91.6k125.2k525.02.5k26.2k7.4k247.9k183.015.023.7k369.4k22.1k16.041.8k8.5k158.5k5.0k248.9k

Accounts Receivable

21.5k23.8k12.8k18.0k23.8k359.0

Prepaid Expenses

15.8k8.9k4.7k38.6k7.7k4.1k14.1k6.4k24.1k27.3k26.9k20.8k26.2k26.3k20.8k29.5k30.5k6.8k6.8k7.5k11.1k15.5k39.8k38.5k7.1k50.7k

Inventories

7.8k14.9k6.5k10.9k3.6k8.5k8.5k8.5k8.5k8.5k8.5k8.5k8.5k8.5k8.5k8.5k8.5k
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(2.7m)(8.6m)(3.5m)(18.1m)6.2m(9.9m)(6.4m)(7.7m)(1.6m)

Depreciation and Amortization

546.4k483.2k208.6k12.0k5.7k2.9k1.5k

Inventories

8.3k(5.6k)4.4k

Accounts Payable

619.6k397.8k205.6k240.0k151.6k103.0k102.3k(1.3k)(136.4k)
USDQ2, 2011

Financial Leverage

-0.4 x
Show all financial metrics

Vivos Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Vivos Online and Social Media Presence

Embed Graph

Vivos News and Updates

Vivos Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering

HIGHLANDS RANCH, Colorado, Oct. 09, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- Vivos Therapeutics, Inc. (“Vivos”), a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, today announced that is has filed a registration st…

Vivos Inc Initiates IsoPet Therapy of Horses – Addressing Unmet Need for the Treatment of Equine Tumors

Richland WA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it is expanding Isopet® into the equine market by making IsoPet® available to treat solid tumors in horses. The most common tumors are equoids and sarcomas. This is an important ex…

Vivos Inc Provides Update on Initial Indication for Use for RadioGelTM Therapy

Richland WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), We are excited to announce that based on the recommendation of our Medical Advisory Board, Vivos Inc has decided on treating inaccessible (non-resectable) cancerous lymph nodes, particularly in the head, neck, and lungs as it…

Vivos Inc Reports Additional IsoPet Therapies

Richland WA, July 30, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Interest in IsoPet therapy is increasing. Yesterday Vivos Inc treated “Mister Motto” a cat that the pet parents flew to the state of Washington from New York City. As interest and awareness continues to increase, pet parents …

Vivos Inc Achieves Important Radiogel™ Development Milestones

Richland WA, June 24, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos announced today significant progress in its efforts to advance RadioGel™ for human therapy. Animal testing at the University of Missouri was completed in 2019. Since then we have been focusing on completing the Radiogel…

Sleep Apnea Company Vivos Therapeutics Successfully Launches Online Training to Healthcare Professionals During Pandemic

Vivos Therapeutics' powerful online education and training program sees surge in demand from over 4,300 dental and medical professionals
Show more

Vivos Blogs

Vivos Inc. Announces Listing to the OTCQB

Vivos Inc. Announces Listing to the OTCQB

Vivos Inc. Stock Symbol Reverts to RDGL University of Missouri Report Near Completion

Vivos Inc. Stock Symbol Reverts to RDGL University of Missouri Report Near Completion

Vivos Inc. Pilot Clinic Completes First IsoPet® Therapy

Vivos Inc. Pilot Clinic Completes First IsoPet® Therapy

Vivos Inc. Pilot Clinic Completes Their Certification Training

Vivos Inc. Pilot Clinic Completes Their Certification Training

Vivos Inc. Enhances its Intellectual Property Protection

Vivos Inc. Enhances its Intellectual Property Protection

Vivos Inc. Announces 1-for-8 Reverse Stock Split

Vivos Inc. Announces 1-for-8 Reverse Stock Split
Show more

Vivos Frequently Asked Questions

  • When was Vivos founded?

    Vivos was founded in 2006.

  • Who are Vivos key executives?

    Vivos's key executives are Carlton Cadwell, Michael Pollack and Mike Korenko.

  • How many employees does Vivos have?

    Vivos has 2 employees.

  • What is Vivos revenue?

    Latest Vivos annual revenue is $9.5 k.

  • What is Vivos revenue per employee?

    Latest Vivos revenue per employee is $4.8 k.

  • Who are Vivos competitors?

    Competitors of Vivos include aspUraclip, Ecomed and DCC Vital.

  • Where is Vivos headquarters?

    Vivos headquarters is located at 719 Jadwin Ave, Richland.

  • Where are Vivos offices?

    Vivos has an office in Richland.

  • How many offices does Vivos have?

    Vivos has 1 office.